AstraZeneca: agrees to new deal with Oxford Biomedica

(CercleFinance.com) - Gene and cell therapy firm Oxford Biomedica said on Friday that it has signed a new three year agreement with AstraZeneca to facilitate the manufacturing of the global biopharmaceutical company's Covid-19 vaccine.


Under the new agreement, manufacturing of vaccines at Oxford Biomedica's 84,000 square feet manufacturing facility will be available to AstraZeneca on an as-needed basis beyond 2022.

The deal is an expansion of the original supply agreement that was announced in September 2020, as the manufacture of AstraZeneca's Covid vaccine at Oxford Biomedica's facility is expected to complete in the last quarter of 2022.

Copyright (c) 2022 CercleFinance.com. All rights reserved.